Why the study?
The review aimed to synthesize current research on epicardial adipose tissue, secreted adipokines, their metabolic effects, and their relationship with cardiovascular diseases.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Epicardial adipose tissue acts as a metabolically active endocrine organ whose dysregulation contributes to cardiovascular disease pathogenesis, making it a valuable biomarker and potential therapeutic target.
Epicardial adipose tissue (EAT) has unique properties due to its special anatomical structure, thermoregulation, and metabolic activity. Dysregulated EAT provokes the synthesis of pro-inflammatory cytokines, disorders in the metabolism of fats and glucose, as well as contributes to fatty degeneration of the myocardium and heart failure development. EAT may serve as a risk factor and biomarker for cardiovascular diseases, and is also a potential therapeutic target. The purpose of this review was to highlight current research data on EAT, secreted adipokines, their effect on target tissue metabolism, and to systematize the relationship between EAT and cardiovascular diseases. In particular, its function, role in heart failure, atrial fibrillation, as well as the prognostic value of various microRNAs determined in EAT are highlighted.
No takes yet. Share an insight, caveat, or question.
Mustafina et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: